Questions answered include:
- Which states and metropolitan statistical areas have the greatest number of patients with insurance?
- How many patients have the disease but are not treated in each territory?
- How many insured patients would be gained in each local market if territories with poor treatment rates were brought up to the national average?
- Disease-specific prevalence numbers for each U.S. state and metropolitan statistical area
- Examination of treatment rates for the disease population to create percent treated and percent untreated estimates by state and metropolitan statistical area
- Unique analysis of the untreated population examined through a filter of Rx benefit coverage. The end result is an estimate of how many patients are untreated but can afford therapy within each territory—the true local measure of opportunity for pharma companies
- Population breakdown by age, gender,race and socioeconomic status
- Insured population
- Uninsured as percent of population
- Insured with Rx benefit
- Prevalence of disease
- Prevalence as percent of population
- Treated for disease
- Treated as percent of population
- Untreated for disease
- Untreated as percent of population
- Untreated with Rx benefit